AIM share code: SKIN

25 March 2019

Integumen PLC

("Integumen" or "Company")

Labskin CBD tests show increase in procollagen and reduction in inflammatory skin irritation

Integumen announces the positive results of further tests in formulations, as indicated in its announcement of 20 February 2019. These formulations, all of which contain low-concentrations of hemp-derived Cannabinoid (CBD) oils, increase production of pro-collagen in as little as 24 hours, and indicate a reduction of inflammation on Labskin leading to a soothing effect on irritated and sore skin.

Pro-Collagen:

Pro-collagen has been shown to improve the youthfulness of skin appearance and is a precursor of collagen, the protein that adds strength and support to body tissue. The amount of pro-collagen production can be directly measured, as no additional collagen is added to the Labskin model.

Anti-inflammatory properties:

Inflammation, or the painful reddening and swelling of the skin, can be caused by a variety of reasons from bacterial infection to irritation from harsh skin products. Labskin is capable of releasing chemical markers that indicate inflammation damage occurring on the skin test model. The trial data shows that formulations containing hemp-derived CBD oil, in low concentrations, reduce the release of these inflammation markers indicating a soothing effect on sore skin.

Updated test results

The Company trading updates of 7 January 2019 and 20 February noted that Cellulac (9.35% owned by Integumen) had developed a low-cost hemp-derived CBD oil extraction process and was collaborating with Labskin to provide a formulation for the STOER For Men range of cosmetics.

Gerard Brandon (Chief Executive Officer) commented:

"Scientific evidence to back up anti-ageing or problematic skin treatments is far superior to anecdotal percentages of product testers. With no animal testing allowed, consumers still have a right to know what the real impact and effect of products have on their skin, before they use it.

Further tests and product approvals are still required before consideration of launching an extension to the range of STOER For Men skin care products. Labskin is now offering the same test services to clients adding CBD to their skin-care and cosmetic range of products."

About Integumen:

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

Notes to Editors:

CBD (Cannabidiol) oil is an extract from the Cannabis Sativa plant. Hemp-derived CBD is produced from the seeds of the plant, and does not contain the psychoactive ingredient Tetrahydrocannabinol (THC) or does so only in trace amounts. This differentiates hemp-derived CBD oil from CBD Oil produced from flowers, leaves and stalks of the plant (which are higher in THC content). CBD products which contain less than 0.2% THC concentration are legal in the UK.

The European Food Standard Agency entry for "Cannabinoids" now states "extracts of Cannabis Sativa L. and derived products containing cannabinoids are considered novel foods as a history of consumption has not been demonstrated. This applies to both the extracts themselves and any products to which they are added as an ingredient (such as hemp seed oil)." This means that CBD supplements are now deemed to be novel food in Europe.

http://ec.europa.eu/food/safety/novel_food/catalogue/search/public/index.cfm

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.